In a single-blind, crossover design study involving 20 subjects (mean age = 64 years) with well-controlled type 2 diabetes, results indicate that long-term supplementation with Salba - a novel whole-grain (Salvia hispanica L.), rich in fiber, alpha-linolenic acid and minerals - may lower systolic blood pressure and certain other cardiovascular risk factors. Using a crossover design, the subjects were randomized to receive either 37 g/day Salba or wheat bran (control) for a period of 12 weeks, while remaining on their conventional diabetes therapies. Salba supplementation was found to significantly reduce systolic blood pressure (-6.3 mm Hg), hs-CRP (-40%) and von Willebrand factor (-21%), compared with the control. Additionally, significant decreases in A1c and fibrinogen were observed at Salba-intervention end, compared to Salba-intervention baseline. No changes in safety parameters were associated with Salba supplementation. Thus, the authors of this study conclude, "Long-term supplementation with Salba attenuated a major cardiovascular risk factor (SBP) and emerging factors (hs-CRP and vWF) safely beyond conventional therapy, while maintaining good glycemic and lipid control in people with well-controlled type 2 diabetes."